August 9, 2022 Tags: Plastic Surgery News
Back in January 2022, Juvéderm Volux, a new hyaluronic acid filler, began being tested in the United States to provide more definition to the lower face. On August 3, 2022, Allergan Aesthetics, an AbbVie company, announced that Juvéderm Volux was approved by the Food and Drug Administration (FDA) for use along the jawline.
Hyaluronic acid fillers have been used in the jawline area for years off-label, but Volux is the first FDA-approved product for this area of the face. Radiesse (+) is already FDA-approved for the jawline area; however, Radiesse is made of calcium hydroxylapatite, which means that while Radiesse is a longer-lasting filler, it’s not reversible. In contrast, Volux lasts up to six months and is firmer and thicker than hyaluronic acid fillers designed for the lips, cheeks, and chin. Like all hyaluronic acid fillers, Volux injections are reversible using hyaluronidase.
Experts are excited about the arrival ofJuvéderm Volux, citing its popularity in Europe and Allergan as reasons to add it to their hyaluronic acid lines. The stiffness of the filler makes it unlike others currently on the market and is perfect for creating a beautiful and youthful jawline.